Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFX 1
- Development stage
- Preclinical
- Lead developer
- Mestastop
- Modality
- Small Molecules
01
Overview
TFX 1 is a preclinical-stage small molecule drug candidate being developed by Mestastop Solutions for the treatment of cancer metastasis, specifically in colorectal cancer and triple-negative breast cancer. TFX 1 targets TFX1, a first-in-class transcription factor target identified through Mestastop's proprietary METAssay™ platform. Overexpression of TFX1 in cancer cells has been shown to increase metastatic properties such as migration, invasion, autophagy, and platelet binding, while downregulation or pharmacological inhibition of TFX1 reverses these effects. The program is currently in the Hit-to-Lead / IND-enabling stage of development.
- Other names
- TFX1TFX-1TFX 1
02
Targets
TFX1 (TFX1 transcription factor)
Beyond the preview
Go deeper on TFX 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TFX 1.